Exenatide enhances standard therapy in type 2 diabetes mellitus

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1445, 2004-01, pp. : 7-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus

By Gallwitz Baptist

Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. : 87-100

Adis International

Access to resources Recommend Favorite

Exenatide once weekly in type 2 diabetes mellitus

By Bischoff Lindsay A Jabbour Serge A Miller Jeffrey L

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 8, 2011-06 ,pp. : 1297-1303

Informa Healthcare

Access to resources Recommend Favorite

Exenatide: a GLP-1 receptor agonist as novel therapy for Type 2 diabetes mellitus

By Briones Mariele Bajaj Mandeep

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 8, 2006-06 ,pp. : 1055-1064

Informa Healthcare

Access to resources Recommend Favorite

Exenatide Extended-Release: A Review of Its Use in Type 2 Diabetes Mellitus

By Scott Lesley J.

Drugs, Vol. 72, Iss. 12, 2012-08 ,pp. : 1679-1707

Adis International

Access to resources Recommend Favorite

Combination lipid therapy in type 2 diabetes mellitus

By Vergèès Bruno

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 9, 2011-06 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite